Emerging antifungal agents in human medicine: Mechanisms, clinical progress, and future perspectives.

Fungal infections remain a major global health challenge, particularly among immunocompromised patients, with increasing morbidity and mortality driven by invasive candidiasis, aspergillosis, cryptococcosis, and emerging multidrug-resistant pathogens such as Candida auris. Although conventional antifungal classes, including azoles, echinocandins, polyenes, and flucytosine, remain central to antifungal therapy, their clinical utility is limited by toxicity, drug-drug interactions, restricted spectra, variable pharmacokinetics, and the growing emergence of antifungal resistance. These limitations have highlighted the urgent need for novel antifungal agents with improved safety profiles, new mechanisms of action, broader or more targeted activity, and optimized pharmacokinetic properties. This narrative review summarizes the current landscape of emerging antifungal therapies, focusing on ibrexafungerp 1, rezafungin 2, fosmanogepix 3, olorofim 4, opelconazole 5, and oteseconazole 6. Their mechanisms of action, antifungal spectra, resistance profiles, preclinical evidence, clinical development, pharmacokinetic advantages, and safety data are discussed and compared with established antifungal classes. Several of these agents introduce entirely novel antifungal targets, including inhibition of fungal dihydroorotate dehydrogenase and Gwt1-mediated glycosylphosphatidylinositol-anchor biosynthesis, while others optimize existing antifungal strategies through prolonged half-life, improved fungal selectivity, oral bioavailability, or inhaled pulmonary delivery. Collectively, these emerging antifungal agents expand therapeutic options against resistant Candida species, azole-resistant Aspergillus fumigatus (A.fumigatus), and difficult-to-treat molds, while potentially improving tolerability and reducing interaction-related limitations. However, important challenges remain, including limited activity against Mucorales for several agents, the potential emergence of future resistance, and the need for additional comparative clinical data and real-world experience. Overall, the expanding antifungal pipeline represents a major advancement toward more targeted and individualized antifungal therapy and may significantly reshape the future management of invasive and refractory fungal infections.